EXOZ
EXOZYMES INC.Figures below are compared against other companies classified under Biological Products, (No Diagnostic Substances).
Grades vs. industry
Profitability
| Metric | Company | Industry median | Rank |
|---|---|---|---|
Gross margin Gross profit as a share of revenue. Often unreported. | Not reported | 74.3% | — |
Operating margin Operating income as a share of revenue. | Not reported | -19.1% | — |
Net margin Net income as a share of revenue. | Not reported | -17.7% | — |
Free cash flow margin Free cash flow as a share of revenue. | Not reported | -22.3% | — |
Return on equity Net income divided by shareholder equity. | -269.6% | -16.5% | — |
Return on assets Net income divided by total assets. | -153.4% | -8.0% | — |
Return on invested capital After-tax operating profit over debt plus equity less cash. | -2144.7% | -13.0% | — |
“Not reported” means the company did not tag this figure in its filing, not that the value is zero. Nothing here is ranked: this company reported an operating loss several times its revenue, so it is left out of its industry’s comparisons and does not count toward the medians shown. Its own figures are exactly as filed.
Financial health
| Metric | Company | Industry median | Rank |
|---|---|---|---|
Debt to equity Total debt divided by shareholder equity. | Not reported | 0.29x | — |
Current ratio Current assets over current liabilities. | 2.51x | 3.75x | — |
Quick ratio Current assets excluding inventory, over current liabilities. | 2.51x | 3.34x | — |
Interest coverage Operating income divided by interest expense. | Not reported | 0.52x | — |
Net debt to EBITDA Net debt over derived EBITDA. EBITDA is not a GAAP tag; it is computed. | Not reported | -1.02x | — |
“Not reported” means the company did not tag this figure in its filing, not that the value is zero. Nothing here is ranked: this company reported an operating loss several times its revenue, so it is left out of its industry’s comparisons and does not count toward the medians shown. Its own figures are exactly as filed.
Insider activity
Trades reported by officers, directors and 10% shareholders on SEC Form 4. 5 of the last 17 reported transactions were open-market purchases; the rest are mostly sales and compensation.
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 1, 2026 | BELL LON E Director | Grant or award(derivative) | 10,000 | $0.00 | $0.00 |
| Oct 1, 2026 | Bowie James Ulrich Director | Grant or award(derivative) | 10,000 | $0.00 | $0.00 |
| Oct 1, 2026 | Lalonde James Joseph Director | Grant or award(derivative) | 10,000 | $0.00 | $0.00 |
| Oct 1, 2026 | MARLETT CHRISTOPHER A Director, 10% owner | Grant or award(derivative) | 10,000 | $0.00 | $0.00 |
| Oct 1, 2026 | Rayo Edgardo Javier Director | Grant or award(derivative) | 25,000 | $0.00 | $0.00 |
| Oct 1, 2026 | DIGIANDOMENICO ANTHONY Director, 10% owner | Grant or award(derivative) | 10,000 | $0.00 | $0.00 |
| Sep 14, 2026 | Nawaz Fouad Vice President- Finance | Grant or award(derivative) | 45,000 | $0.00 | $0.00 |
| Aug 26, 2026 | Heltzen Michael Chief Executive Officer | Open-market purchase | 250 | $7.60 | $1.9K |
| Aug 26, 2026 | Heltzen Michael Chief Executive Officer | Open-market purchase | 251 | $7.35 | $1.8K |
| Aug 26, 2026 | Heltzen Michael Chief Executive Officer | Open-market purchase | 4 | $7.58 | $30.32 |
| Aug 25, 2026 | Heltzen Michael Chief Executive Officer | Open-market purchase | 250 | $7.52 | $1.9K |
| Aug 25, 2026 | Heltzen Michael Chief Executive Officer | Open-market purchase | 100 | $7.50 | $750.00 |
| Aug 19, 2026 | Heltzen Michael Chief Executive Officer | Grant or award | 8,841 | $6.40 | $56.6K |
| Aug 19, 2026 | Perriman Damien Alan Chief Commercial Officer | Option exercise(derivative) | 19,612 | $0.00 | $0.00 |
| Aug 19, 2026 | Korman Tyler Paz Chief Scientific Officer | Option exercise(derivative) | 32,964 | $0.00 | $0.00 |
| Aug 19, 2026 | Perriman Damien Alan Chief Commercial Officer | Option exercise | 19,612 | — | — |
| Aug 19, 2026 | Korman Tyler Paz Chief Scientific Officer | Option exercise | 32,964 | — | — |
A dash under price or value means none was reported, which is normal for grants and gifts — it does not mean the shares were free. Option exercises and awards are compensation arriving on a schedule, not a judgement about the stock.
Annual financials
| Fiscal year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | — | — | $70.1K |
| Operating income | -$9.72M | -$5.93M | -$1.80M |
| Net income | -$9.16M | -$5.86M | -$2.04M |
| EPS (diluted) | -$1.09 | -$0.89 | -$0.33 |
| Operating cash flow | -$6.50M | -$8.51M | -$1.18M |
| Capital expenditure | $169.9K | $396.5K | $288.7K |
| Free cash flow | -$6.67M | -$8.90M | -$1.47M |
| Total assets | $5.97M | $13.03M | $3.56M |
| Shareholder equity | $3.40M | $10.42M | -$384.3K |
| Cash | $3.04M | $9.72M | $66.5K |
A dash means the figure was not tagged in that year’s filing. It does not mean zero. Figures reflect the most recent filing covering each period, so restated years show their restated values.
Source
Figures come from EXOZYMES INC.’s filings with the SEC, as submitted in XBRL. The most recent annual figures are from a 10-K filed Mar 30, 2026. View filings on EDGAR.